Industry Changing Innovations


“Arthramid® Vet is used everyday and around the world for the treatment of lameness in horses. Multiple published studies from high profile institutions, and treating hundreds of equine patients across all equestrian disciplines, show that Arthramid®Vet is a safe and effective treatment for osteoarthritis and joint lameness in animals. Explore this page for more information and to access findings from studies of Arthramid® Vet 2.5% PAAG”

Efficacy Study- Double Blind Positive Control

Prospective Clinical Trial

Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking equestrian disciplines. To date, there have been no studies evaluating the effect of positive control treatments in racehorses compared to 2.5% PAAG.

Objectives: To investigate the efficacy of a 2.5% PAAG (Arthramid Vet) in the management of inter-carpal joint lameness in racing Thoroughbreds.

Study design: Prospective double-blinded positive-control study.

(read more)

2.5% PAAG – Joint Lameness & Osteoarthritis (OA) In Horses

Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses. 1, 2 Clinically, it is associated with lameness and dysfunction of the affected joint and approximately 60% of all equine lameness is due to OA. 3, 4It is characterised by breakdown and loss of joint cartilage, bony overgrowths (osteophytosis- seen on radiographs), (read more)

  • Novel treatment for lameness.
  • Treats underlying disease process.
  • Positive effect on articular components.
  • Reduces mechanoreceptor activation.
  • Long lasting tissue compatibility.

Clinical Safety In Application – Case Studies

Both in vitro and in vivo studies have taken place, designed to generate data on the safety of Arthramid Vet and to support regulatory submissions for market authorisation. Most current OA treatments are focused on reducing symptoms, and there are few effective treatments that address the underlying cause of the disease. (read more)

  • Multiple Safety Studies.
  • Neuro-innocuous.
  • No adverse side effects.
  • Widespread use in human medicine.
  • Safe for competiton.

Mechanism Of Action – Compared To Conventional Therapies

Arthritis describes inflammation of a joint and can happen after either a single or repetitive episodes of trauma. 31 The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis or OA. These pathological conditions are ‘a group of overlapping distinct diseases which may have different causes, but with similar biologic, anatomical, and clinical outcomes.’ (read more)

  • Integrates into joint capsule.
  • Restoring function to the joint.
  • Increasing visco-elastic.
  • Reduces pain & synovitis.
  • Stable & non-absorbable.

Comments From Clinical Practice

I have been using Arthramid Vet for 4 years treating TB’s,SB’s and equestrian horses.90 % of my work is lameness identification and treatment.I have injected over 600 joints with Arthramid Vet and have experienced no side affects.I have used all of the alternative joint treatments over the last 50 years and consider Arthramid Vet… (read full)

I was one of the first vets to use Arthramid worldwide and have now used Arthramid for over 10 years in our clinic. We have injected over a thousand horses and have found it to be very safe. It has been a major game-changer in the way we treat OA in our patients. We have fantastic results with really frustrating cases and are still working on… (read full)

Get In Touch

I am Interested In

Order Request

32 Hill Road, Cambridge, NZ
Phone +64 (09) 8013 253

Innovative Medical Solutions

Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See  for registration conditions.

32 Hill Road, Cambridge
PO Box 1083, Cambridge 3450
Phone +64 (09) 8013 253